Faraday Future Intelligent Electric Inc. filings document the public-company disclosures of an electric vehicle and Embodied AI company with Class A common stock and redeemable warrants listed on Nasdaq. Its regulatory record includes material-event reports, proxy materials, operating and financial results, and governance disclosures.
Recent filings cover material definitive agreements, secured promissory notes, loan and securities purchase arrangements, preferred stock matters, executive and board changes, shareholder meeting proposals, director elections, Nasdaq share-issuance approvals, risk factors, capital structure, and securities registered for trading under the FFAI and FFAIW symbols.
Faraday Future Intelligent Electric Inc. reported a planned strategic investment in Qualigen Therapeutics. On September 19, 2025, the company agreed to invest approximately $40.7 million, payable in cash, USDC stablecoin or other cryptocurrencies, to purchase Qualigen common stock at $2.246 per share and/or Series B preferred stock at $1,000 per share. At closing, Faraday Future will gain the right to designate multiple Qualigen directors, including the board chair, and have its designees appointed as Co‑CEO and CFO of Qualigen.
Qualigen must file a resale registration statement for the purchased securities within 45 days and seek stockholder approval by late October 2025 or November 2025, with repeated meetings required until approval is obtained. Separately, Faraday Future shareholders approved amendments increasing authorized common stock from 167,245,313 to 232,470,985 shares and authorized preferred stock from 12,900,000 to 17,931,000 shares, and added 9,500,000 shares to the 2021 stock incentive plan, while rejecting a proposed name change.